GILEAD SCIENCES, INC. Line of Credit Facility, Maximum Borrowing Capacity
GILEAD SCIENCES, INC. (GILD) had Line of Credit Facility, Maximum Borrowing Capacity of $1.25 billion as of 2011-12-31, per its 10-K filed 2012-02-23.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2012-02-23
- 2011-12-31: Line of Credit Facility, Maximum Borrowing Capacity $1.25B.
- 2011-09-30: Line of Credit Facility, Maximum Borrowing Capacity $1.25B.
- 2011-06-30: Line of Credit Facility, Maximum Borrowing Capacity $1.25B.
- 2011-03-31: Line of Credit Facility, Maximum Borrowing Capacity $1.25B.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2011-12-31 | $1.25B 10-K · filed 2012-02-23 |
| 2011-09-30 | $1.25B 10-Q · filed 2011-11-04 |
| 2011-06-30 | $1.25B 10-Q · filed 2011-08-05 |
| 2011-03-31 | $1.25B 10-Q · filed 2011-05-09 |
| 2010-12-31 | $1.25B 10-K · filed 2011-02-28 |
| 2010-09-30 | $1.25B 10-Q · filed 2010-11-08 |
| 2010-06-30 | $1.25B 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |